- Home
- SPRO vs IHRT Comparison
SPRO vs IHRT Comparison
Compare SPRO & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- IHRT
- Stock Information
- Founded
- SPRO 2013
- IHRT 1974
- Country
- SPRO United States
- IHRT United States
- Employees
- SPRO N/A
- IHRT N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- IHRT Broadcasting
- Sector
- SPRO Health Care
- IHRT Consumer Discretionary
- Exchange
- SPRO Nasdaq
- IHRT Nasdaq
- Market Cap
- SPRO 164.4M
- IHRT 193.4M
- IPO Year
- SPRO 2017
- IHRT 2019
- Fundamental
- Price
- SPRO $2.91
- IHRT $2.05
- Analyst Decision
- SPRO Buy
- IHRT Buy
- Analyst Count
- SPRO 4
- IHRT 3
- Target Price
- SPRO $5.00
- IHRT $2.92
- AVG Volume (30 Days)
- SPRO 1.6M
- IHRT 940.3K
- Earning Date
- SPRO 08-04-2025
- IHRT 08-07-2025
- Dividend Yield
- SPRO N/A
- IHRT N/A
- EPS Growth
- SPRO N/A
- IHRT N/A
- EPS
- SPRO N/A
- IHRT N/A
- Revenue
- SPRO $44,584,000.00
- IHRT $3,862,595,000.00
- Revenue This Year
- SPRO N/A
- IHRT N/A
- Revenue Next Year
- SPRO N/A
- IHRT $5.89
- P/E Ratio
- SPRO N/A
- IHRT N/A
- Revenue Growth
- SPRO N/A
- IHRT 3.31
- 52 Week Low
- SPRO $0.51
- IHRT $0.95
- 52 Week High
- SPRO $3.09
- IHRT $2.84
- Technical
- Relative Strength Index (RSI)
- SPRO 71.62
- IHRT 70.79
- Support Level
- SPRO $2.79
- IHRT $1.64
- Resistance Level
- SPRO $3.03
- IHRT $1.95
- Average True Range (ATR)
- SPRO 0.12
- IHRT 0.15
- MACD
- SPRO -0.08
- IHRT 0.01
- Stochastic Oscillator
- SPRO 43.75
- IHRT 80.81
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About IHRT iHeartMedia Inc.
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.